MX2025003741A - Esquema de dosificacion de sotorasib - Google Patents

Esquema de dosificacion de sotorasib

Info

Publication number
MX2025003741A
MX2025003741A MX2025003741A MX2025003741A MX2025003741A MX 2025003741 A MX2025003741 A MX 2025003741A MX 2025003741 A MX2025003741 A MX 2025003741A MX 2025003741 A MX2025003741 A MX 2025003741A MX 2025003741 A MX2025003741 A MX 2025003741A
Authority
MX
Mexico
Prior art keywords
sotorasib
patient
dosage scheme
dosage
scheme
Prior art date
Application number
MX2025003741A
Other languages
English (en)
Spanish (es)
Inventor
Brett E Houk
Panli Cardona
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2025003741A publication Critical patent/MX2025003741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2025003741A 2022-09-30 2025-03-28 Esquema de dosificacion de sotorasib MX2025003741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
PCT/US2022/053130 WO2024072437A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Publications (1)

Publication Number Publication Date
MX2025003741A true MX2025003741A (es) 2025-05-02

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025003741A MX2025003741A (es) 2022-09-30 2025-03-28 Esquema de dosificacion de sotorasib

Country Status (9)

Country Link
US (1) US20260083741A1 (https=)
EP (1) EP4593837A1 (https=)
JP (1) JP2025533334A (https=)
KR (1) KR20250079183A (https=)
AU (1) AU2022479909A1 (https=)
JO (1) JOP20250064A1 (https=)
MX (1) MX2025003741A (https=)
TW (1) TW202415380A (https=)
WO (1) WO2024072437A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Also Published As

Publication number Publication date
TW202415380A (zh) 2024-04-16
US20260083741A1 (en) 2026-03-26
EP4593837A1 (en) 2025-08-06
AU2022479909A1 (en) 2025-02-06
KR20250079183A (ko) 2025-06-04
WO2024072437A1 (en) 2024-04-04
JOP20250064A1 (ar) 2025-03-25
JP2025533334A (ja) 2025-10-06

Similar Documents

Publication Publication Date Title
Kim et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
Shanafelt et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912)
JOP20210172B1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
EA202092154A1 (ru) Комбинированная терапия
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
WO2016051398A8 (en) Patient-specific immunotherapy for treating heterogeneous tumors
RU2013121744A (ru) Лечение рака/ингибирование метастазирования
JOP20210125A1 (ar) إيلاسيسترانت بالاشتراك مع أبيماسيكليب عند النساء المصابات بسرطان الثدي
RU2013126036A (ru) Способ лечения опухолей
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
NI201700024A (es) Tratamientos médicos a base de anamorelina
RU2014109999A (ru) Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
MX2025003741A (es) Esquema de dosificacion de sotorasib
CU22979A1 (es) Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
MX2025006565A (es) Terapia contra el cancer con capivasertib y fulvestrant
ATE409039T1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
JOP20240049A1 (ar) سوتوراسيب وجسم مضاد لـ egfr لعلاج سرطان يشمل طفرة kras g12c
Hamzelou et al. Superficial plantar angiomyxoma in a young man.
EA202191273A1 (ru) Применение тивозаниба для лечения субъектов с рефрактерным раком
NO20064755L (no) Kombinasjonsterapi
Yin et al. Incidence of second malignancies of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors